scholarly journals Antibody Response to Canine Parvovirus Vaccination in Dogs with Hyperadrenocorticism Treated with Trilostane

Vaccines ◽  
2020 ◽  
Vol 8 (3) ◽  
pp. 547 ◽  
Author(s):  
Michèle Bergmann ◽  
Monika Freisl ◽  
Katrin Hartmann ◽  
Stephanie Speck ◽  
Uwe Truyen ◽  
...  
Keyword(s):  
Immune Response ◽  
Adverse Events ◽  
Antibody Response ◽  
Matched Control ◽  
Univariate Analysis ◽  
Fold Increase ◽  
Canine Parvovirus ◽  
Significant Difference ◽  
Before And After ◽  
Healthy Dogs

It is unknown how dogs with hyperadrenocorticism (HAC) respond to vaccination. This study measured antibodies against canine parvovirus (CPV) in dogs with HAC treated with trilostane before and after CPV vaccination, and compared the immune response to that from healthy dogs. Eleven dogs with HAC, and healthy age-matched control dogs (n = 31) received a modified-live CPV vaccine. Antibodies were determined on days 0, 7, and 28 by hemagglutination inhibition. Univariate analysis was used to compare the immune response of dogs with HAC and healthy dogs. Pre-vaccination antibodies (≥10) were detected in 100% of dogs with HAC (11/11; 95% CI: 70.0–100) and in 93.5% of healthy dogs (29/31; 95% CI: 78.3–99.2). No ≥4-fold increase in antibody titer was observed in dogs with HAC while in 22.6% of healthy dogs, a ≥4-fold titer increase was observed (7/31; 95% CI: 11.1–40.1). Mild vaccine-associated adverse events (VAAEs) were detected in 54.5% of dogs with HAC (6/11; 95% CI: 28.0–78.8) and in 29.0% of healthy dogs (9/31; 95% CI: 15.9–46.8). There was neither a significant difference in presence of pre-vaccination antibodies (p = 1.000), or response to vaccination (p = 0.161), nor in the occurrence of VAAEs (p = 0.158). Immune function of dogs with HAC treated with trilostane seems comparable to that of healthy dogs.

scholarly journals Antibody Response to Canine Parvovirus Vaccination in Dogs with Hypothyroidism Treated with Levothyroxine

Vaccines ◽  
2021 ◽  
Vol 9 (2) ◽  
pp. 180
Author(s):  
Michèle Bergmann ◽  
Monika Freisl ◽  
Katrin Hartmann ◽  
Stephanie Speck ◽  
Uwe Truyen ◽  
...  
Keyword(s):  
Adverse Events ◽  
Antibody Response ◽  
Matched Control ◽  
Univariate Analysis ◽  
Canine Parvovirus ◽  
Post Vaccination ◽  
Vaccination Response ◽  
Significant Difference ◽  
Healthy Dogs ◽  
Modified Live Vaccine

(1) Background: No information is available on how dogs with hypothyroidism (HypoT) respond to vaccination. This study measured pre- and post-vaccination anti-canine parvovirus (CPV) antibodies in dogs with HypoT treated with levothyroxine and compared the results to those of healthy dogs. (2) Methods: Six dogs with HypoT and healthy age-matched control dogs (n = 23) were vaccinated against CPV with a modified-live vaccine. Hemagglutination inhibition was used to measure antibodies on days 0, 7, and 28. The comparison of the vaccination response of dogs with HypoT and healthy dogs were performed with univariate analysis. (3) Results: Pre-vaccination antibodies (≥10) were detected in 100% of dogs with HypoT (6/6; 95% CI: 55.7–100) and in 100% of healthy dogs (23/23; 95% CI: 83.1–100.0). A ≥4-fold titer increase was observed in none of the dogs with HypoT and in 4.3% of the healthy dogs (1/23; CI95%: <0.01–22.7). Mild vaccine-associated adverse events (VAAEs) were detected in 33.3% of the dogs with HypoT (2/6; 95% CI: 9.3–70.4) and in 43.5% (10/23; 95% CI: 25.6–63.2) of the healthy dogs. (4) Conclusions: There was neither a significant difference in the dogs’ pre-vaccination antibodies (p = 1.000), or vaccination response (p = 0.735), nor in the occurrence of post-vaccination VAAEs (p = 0.798). The vaccination response in dogs with levothyroxine-treated HypoT seems to be similar to that of healthy dogs.

scholarly journals Antibody response to Salmonella typhi lw human Schistosomiasis mansoni

1996 ◽  
Vol 29 (5) ◽  
pp. 441-445 ◽  
Author(s):  
Maria Imaculada Muniz-Junqueira ◽  
José Tavares-Neto ◽  
Aluizio Prata ◽  
Carlos Eduardo Tosta
Keyword(s):  
Immune Response ◽  
Antibody Response ◽  
Blood Stream ◽  
Salmonella Typhi ◽  
Healthy Individuals ◽  
Typhoid Vaccine ◽  
Schistosomiasis Mansoni ◽  
Positive Antibody ◽  
Before And After ◽  
Hepatosplenic Schistosomiasis

Antibody response to Salmonella typhi O and H antigens was evaluated in 24 individuals with either hepatointestinal or hepatosplenic schistosomiasis mansoni before and after typhoid vaccination, and compared with that of non-infected controls. Before vaccination, Schistosoma-infected patients showed a higher frequency of positive antibody to O antigen and the same frequency to H antigen when compared with that of healthy individuals. However, those with hepatosplenic schistosomiasis showed higher titres of antibody to H antigen than those with hepatointestinal disease or healthy individuals. Infected subjects, particularly those with hepatointestinal disease, showed a decreased response after typhoid vaccine. Tins diminished ability to mount an immune response towards typhoid antigens dining schistosomiasis may interfere ivith the clearance of the bacteria from blood stream and, therefore, play a role in the prolonged survival of salmonella as obsewed in some patients with chronic salmonellosis associated with schistosomiasis.

scholarly journals Peningkatan Status Perkembangan Anak Prasekolah dengan Stimulasi Perkembangan

JKEP ◽  
2020 ◽  
Vol 5 (2) ◽  
pp. 150-160
Author(s):  
Santun Setiawati ◽  
Agus Citra Dermawan ◽  
Raden Siti Maryam
Keyword(s):  
Univariate Analysis ◽  
Wilcoxon Test ◽  
Good Growth ◽  
Frequency Distributions ◽  
Growth Status ◽  
Development Status ◽  
Significant Difference ◽  
Before And After ◽  
Quasi Experimental ◽  
Children Development

The children are not small adults, but have unique characteristics that are always growing and evolving since their conception until the end of adolescence. Good growth and development of children requires appropriate stimulation and accordance with the age such as developmental stimulation. The aim of this study was to determine the influence development simulations towards pre-school children’s growth status. This research was using the quasi-experimental design without control. The numbers of respondents were 30 children (with aged 60-72 month). The children with dubious developmental status had performed the development stimulations for 2 weeks for 3-4 housr a day and evaluated the development status. Developmental Pre-Screening Questionnaire (KPSP) instrument used in this research. The data analysis was using univariate analysis (frequency distributions), bivariate (Wilcoxon test) and multivariate (ANCOVA test). There was a significant difference in the children’s development status before and after development stimulation interventions (p= 0.000), but there was no children and mothers’ characteristic factors that affect the children development status. Stimulation associated with the value of child development, where the high category of stimulation is not found in children whose development category is slow. So it takes stimulation of children from an early age. Growth stimulations can be done routinely as a part of efforts to improve the children development status.

Comparison of the Efficacy, Safety and Tolerability of Azithromycin and Co-Amoxiclav in the Treatment of Acute Periapical Abscesses

1998 ◽  
Vol 26 (5) ◽  
pp. 257-265 ◽  
Author(s):  
CF Adriaenssen
Keyword(s):  
Soft Tissue ◽  
Adverse Events ◽  
Comparative Study ◽  
Clinical Success ◽  
Point Scale ◽  
Once Daily ◽  
Significant Difference ◽  
Before And After ◽  
Dental Practices

The activity, safety and tolerability of the azalide azithromycin were compared with those of co-amoxiclav in the treatment of acute periapical abscesses in adults in an open, randomized, multicentre comparative study. Patients of either sex, recruited from 106 dental practices in Belgium, were aged between 18 and 75 years and had acute periapical abscesses not requiring drainage, confirmed by radiology. Azithromycin was administered as a 500-mg tablet orally once daily for 3 days ( n = 150) and co-amoxiclav as a 625-mg capsule three times daily, for 5–10 days ( n = 153). Both before and after treatment, masticatory pain, percussion pain, headache, and oedema and redness of soft tissue were graded on a four-point scale. Overall clinical success (cure plus improvement) was seen in 131/144 (91%) evaluable patients receiving azithromycin and in 142/148 (96%) receiving co-amoxiclav (difference not significant). There was no significant difference between the two groups in the incidence or severity of adverse events or in the number of discontinuations because of adverse events.

scholarly journals Severe obesity in children as an independent risk factor for perioperative respiratory adverse events during anaesthesia for minor non-airway surgery, a retrospective observational study

2018 ◽  
Vol 28 (2) ◽  
pp. 83-89
Author(s):  
Kavitha Raghavan ◽  
Daphne Xin Ying Moo ◽  
Zihui Tan
Keyword(s):  
Adverse Events ◽  
Fold Increase ◽  
Normal Weight ◽  
Obese Children ◽  
Medical Comorbidities ◽  
Airway Surgery ◽  
Respiratory Airway ◽  
Obstructive Sleep ◽  
Significant Difference ◽  
Severely Obese

Purpose: The purpose of this article is to quantify grades of obesity and their independent effects on perioperative adverse events in children having ambulatory minor non-airway surgery. Methods: After obtaining ethics committee approval, we selected every tenth child aged 2 to 16 years who was identified as having been a day case between January 2012 and December 2014. Weight groups were defined based on age- and gender-specific body mass index (BMI) cutoff points. A sample size of 1102 was calculated to demonstrate a three-fold increase in the primary outcome measure, perioperative respiratory-airway adverse events, among obese children, with a power of 80% and an alpha error of 5%. Chi-squared and Fisher exact tests were used to compare proportions, and independent sample t tests were used to compare means. Results: Severely obese children had a significantly higher incidence of perioperative respiratory-airway adverse events when compared to normal-weight children despite no difference in respiratory and other comorbidity. Obese children had higher prevalence of overall medical comorbidities and obstructive sleep apnoea when compared to normal-weight children and there was no significant difference in the incidence of perioperative respiratory-airway adverse events and other outcome measures between obese and normal-weight children. Conclusions and recommendations: Severely obese children have a higher risk of perioperative respiratory-airway adverse events even during minor non-airway surgery despite absence of medical comorbidities. We recommend the use of age- and sex- specific BMI cutoffs or BMI percentile charts to identify children who are severely obese to anticipate and prevent major respiratory adverse events.

scholarly journals Antibody Response after BNT162b2 Vaccination in Healthcare Workers Previously Exposed and Not Exposed to SARS-CoV-2

2021 ◽  
Vol 10 (18) ◽  
pp. 4204
Author(s):  
Marcello Salvaggio ◽  
Federica Fusina ◽  
Filippo Albani ◽  
Maurizio Salvaggio ◽  
Rasula Beschi ◽  
...  
Keyword(s):  
Antibody Response ◽  
Healthcare Workers ◽  
Antibody Concentration ◽  
Clinical Documentation ◽  
Receptor Binding Domain ◽  
Effective Number ◽  
Significant Difference ◽  
Before And After ◽  
Previous Infection ◽  
Antibody Levels

The Pfizer/BioNtech Comirnaty vaccine (BNT162b2 mRNA COVID-19) against SARS-CoV-2 is currently in use in Italy. Antibodies to evaluate SARS-CoV-2 infection prior to administration are not routinely tested; therefore, two doses may be administered to asymptomatic previously exposed subjects. The aim of this study is to assess if any difference in antibody concentration between subjects exposed and not exposed to SARS-CoV-2 prior to BNT162b2 was present after the first dose and after the second dose of vaccine. Data were retrospectively collected from the clinical documentation of 337 healthcare workers who underwent SARS-CoV-2 testing before and after BNT162b2. Total anti RBD (receptor-binding domain) antibodies against SARS-CoV-2′s spike protein were measured before and 21 days after the first dose, and 12 days after the second dose of BNT162b2. Twenty-one days after the first dose, there was a statistically significant difference in antibody concentration between the two groups, which was also maintained twelve days after the second dose. In conclusion, antibody response after receiving BNT162b2 is greater in subjects who have been previously exposed to SARS-CoV-2 than in subjects who have not been previously exposed to the virus, both after 21 days after the first dose and after 12 days from the second dose. Antibody levels, 21 days after the first dose, reached a titer considered positive by the test manufacturer in the majority of subjects who have been previously infected with SARS-CoV-2. Evaluating previous infection prior to vaccination in order to give the least effective number of doses should be considered.

scholarly journals Elotuzumab Enhances the Th2-Mediated Immune Response of Dendritic Cell Induced By Immunomodulatory Drugs (IMiDs)

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 4342-4342
Author(s):  
Yoshiko Azuma ◽  
Tomoki Ito ◽  
Muneo Inaba ◽  
Kai Imai ◽  
Masaaki Hotta ◽  
...  
Keyword(s):  
Immune Response ◽  
Immune System ◽  
Dendritic Cell ◽  
Humoral Immunity ◽  
Immune Status ◽  
Fold Increase ◽  
Immune Dysfunction ◽  
Th2 Response ◽  
Humoral Immune ◽  
Before And After

Background: Elotuzumab, a humanized IgG1 monoclonal antibody targeting SLAMF7, is useful for the treatment of Relapsed or Refractory multiple myeloma (RRMM) in combination with Lenalidomide (LEN). However, cellular and molecular mechanisms underlying the immunomodulatory effects of elotuzumab still remain largely unclear. We have previously reported that LEN displays immunopotentiating activity that enhances Th2-mediated response at dendritic cell (DC) phase as upstream immune cascade associated with humoral immunity. DCs are pivotal cells in the sense of orchestrating both cell-mediated (linking with Th1) and humoral (linking with Th2) immunity as masters of the immune system. Series of analyses have clarified myeloid DCs (mDCs) play an important role in allergic immune response by the induction of Th2 response. Here, we focused on the effects of elotuzumab in combination with LEN on the function of human mDCs. Methods: Purified blood human CD11+ mDCs from healthy adult volunteers using cell sorting were cultured and analyzed by flow cytometry and ELISA. Serum were obtained from 16 MM patients with before and after elotuzumab therapy. This study was approved by the Institutional Review Board of Kansai Medical University. Results: We found that surface expression of SLAMF7 on mDCs was upregulated in response to Th2-inducing cytokine, thymic stromal lymphopoietin (TSLP) and the expression level was higher in response to TSLP than in response to toll-like receptor ligand R848. Elotuzumab at clinical in vivo plasma concentration of 30 to 300 µg/ml did not affect mDC survival and their CD86 and OX40-ligand expression when stimulated with 0.3 µM LEN and/or TSLP for 24 h. LEN enhanced TSLP-mediated Th2-recruiting chemokine CCL17/TARC from mDCs which functions as chemoattractant for memory Th2 cells and contribute to allergy and humoral immune responses, and elotuzumab significantly enhanced the LEN-mediated production of CCL17/TARC (TSLP+LEN as control vs. TSLP+LEN+100 µg/ml elotuzumab; 1.23 fold increase: p=0.003, and control vs. TSLP+LEN+300 µg/ml elotuzumab; 1.38 fold increase: p=0.038). This finding suggest elotuzumab enhances Th2-mediated immune profile at upstream phase of humoral immunity. In addition, serum CCL17 levels were analyzed in RRMM patients before and after 3 cycle elotuzumab administration (n=16). We found, serum CCL17 levels after elotuzumab administration were significantly higher compared with those before elotuzumab treatment (after; 1512 ± 459 pg/ml vs. before; 402.2 ± 87.4 pg/ml: p = 0.013). Conclusion: MM involves an element of humoral immune dysfunction. Immune status is important for the prognosis of MM, and clinical outcome can be improved by the recovery of immune status. In this context, our data showing the enhancement of Th2-mediated response by elotuzumab provide a plausible explanation for the observed clinical benefit of this antibody-drug in MM. This function of elotuzumab seems to be relevant to the treatment of MM patients under humoral immune dysfunction. Based on our data in focusing on DCs in the immune system, elotuzumab and IMiDs could function as immunostimulators of humoral immunity via mDCs, and this finding elucidated an additional cellular target of elotuzumab. Disclosures Ito: Celgene: Honoraria; Bristol-Myers Squibb: Honoraria, Research Funding.

Plasminogen Activator Release by Oral Contraceptives and Exercise

1977 ◽  
Author(s):  
A. M. Hedlin
Keyword(s):  
Oral Contraceptive ◽  
Plasminogen Activator ◽  
Oral Contraceptives ◽  
Fibrinolytic Activity ◽  
Fold Increase ◽  
Remarkable Difference ◽  
Significant Difference ◽  
Before And After ◽  
Minute Interval ◽  
Blood And Urine Samples

Oral contraceptives are capable of inducing an increase in blood fibrinolytic activity and our study was undertaken in an attempt to determine whether this is accomplished by stimulating the release of plasminogen activator.For this study 25 women, twelve non-users and thirteen users of the oral contraceptive, Demulen, provided blood and urine samples. Samples were obtained following a one-half hour of rest (pre-exercise), and following a 5 minute interval of moderate exercise on a treadmill. Subjects were tested early in the menstrual cycle (when the oral contraceptive was withdrawn) and late in the cycle when Demulen had been used for about two weeks.Plasma plasminogen activator levels were essentially the same for the two groups, early in the cycle, with exercise causing a doubling of the pre-exercise activator level. However, late in the cycle the contraceptive users had a much higher pre-exercise activator level than the non-users, and exercise caused a three-fold increase in this level.Urine plasminogen activator levels were measured in samples obtained before and after exercise. The urine plasminogen activator levels, unlike the plasma plasminogen activator levels, showed no significant difference between non-users and users. An even more remarkable difference was that at both intervals in the cycle and in both groups the urine plasminogen activator level decreased, rather than increased, following exercise.We conclude that the oral contraceptive Demulen does stimulate the release of plasma plasminogen activator but this does not interfere with release of this activator by exercise.

Gastric emptying as assessed by barium-impregnated polyethylene spheres in healthy dogs consuming a commercial kibble ration

2001 ◽  
Vol 37 (5) ◽  
pp. 444-452 ◽  
Author(s):  
OL Nelson ◽  
AE Jergens ◽  
KG Miles ◽  
WF Christensen
Keyword(s):  
Gastric Emptying ◽  
Test Meal ◽  
Lag Phase ◽  
Significant Difference ◽  
Before And After ◽  
Healthy Dogs ◽  
Lag Phases

Barium-impregnated polyethylene spheres (BIPS) were used to assess gastric emptying in medium-sized dogs consuming a commercial kibble ration. Two sizes of spheres were used: 1.5 mm and 5.0 mm in diameter. Ventrodorsal and right lateral recumbent radiographs were taken immediately before and after consumption of the test meal, and then hourly. The lag phase and the time to 25% (GET25), 50% (GET50), and 75% (GET75) gastric emptying of each sized marker were calculated. There was no significant difference between the lag phases of the small and large BIPS. There was a significant difference between the 1.5 and 5.0 markers at GET25, GET50, and GET75 in these medium-sized dogs. In a majority (70%) of the dogs in this study, GET25 of the 1.5-mm marker occurred at 4.73+/-1.44 hours; GET50 (1.5 mm) occurred at 8.29+/-1.62 hours, and GET75 (1.5 mm) occurred at 10.82+/-1.35 hours. The 5.0-mm markers tended to empty erratically and slowly. Four of the eight dogs retained some of the large markers in their stomachs at the end of the study period (24 hours).

Sign in / Sign up

Export Citation Format

Share Document